# Paige

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/paige

- Industry: Software
- Headquarters: New York, US
- Website: www.paige.ai
- Total disclosed funding: $140M
- Latest round: Series C (Jan 14, 2021)
- Investors on record: 7

## About

Paige, Inc. is a US-based company specializing in AI-driven solutions for cancer pathology. Their innovative applications enhance diagnostic workflows and support clinical decision-making for healthcare professionals.Paige, Inc. was founded in 2018 in New York, US, focusing on advanced AI tools for cancer diagnosis. The company has completed a total of 7 funding deals, with the most recent on January 12, 2023, when they raised USD 55.00 mn during their Series C funding round. Investors in this round included Casdin Capital, Catalio Capital Management, Johnson & Johnson Innovation, and KKR. The founding team includes Joseph Boystak, Peter Schüffler, and Thomas Fuchs, with Andy Moye currently serving as CEO.Paige.ai specializes in advanced AI-driven solutions for cancer pathology, providing proprietary applications designed to enhance diagnostic workflows and support clinical decision-making. Their products include the Paige Prostate Suite, Paige Breast Suite, Paige GI Suite, and Paige PanCancer Suite, which utilize foundation models to analyze H&E-stained whole-slide images and identify molecular biomarkers from tissue samples. These applications are tailored to assist pathologists in detecting and classifying various cancers, thereby improving diagnostic accuracy and efficiency. Their technology is utilized by healthcare institutions, laboratories, and researchers across North America and Europe.Paige.ai generates revenue through partnerships with healthcare institutions and laboratories, leveraging licensing agreements to access their AI technology. Their flagship product, Paige Alba™, enhances pathology workflows and establishes ongoing client relationships that may involve subscription access or usage fees. Revenue is derived not only from direct licensing of AI modules but also from services that support custom AI development and regulatory navigation, suggesting a systematic approach to client engagement focused on long-term collaborations.In January 2023, Paige, Inc. raised USD 55.00 mn in their Series C funding to accelerate growth. The company plans to utilize these funds to develop new products and expand their market presence, particularly targeting new geographic regions. Specific future products and their release dates have not been disclosed, but the focus remains on enhancing their AI capabilities and increasing engagement with healthcare institutions globally.

## Funding rounds

- Series C, Jan 14, 2021, $55M — KKR, Johnson & Johnson Innovation, Casdin Capital, Catalio Capital Management
- Series B, Jul 13, 2020, $15M — HealthCare Ventures, Goldman Sachs Asset Management
- Series B, Dec 18, 2019, $45M — HealthCare Ventures, Breyer Capital
- Series A, Feb 5, 2018, $25M — Breyer Capital

## Investors

- Breyer Capital (https://capitalatlas.ai/funds/breyer-capital) — Series A, Series B
- HealthCare Ventures — Series B
- Goldman Sachs Asset Management (https://capitalatlas.ai/funds/goldman-sachs-asset-management) — Series B
- KKR (https://capitalatlas.ai/funds/kkr) — Series C
- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series C
- Casdin Capital (https://capitalatlas.ai/funds/casdin-capital) — Series C
- Catalio Capital Management (https://capitalatlas.ai/funds/catalio-capital-management) — Series C